Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML) (Q73421046)
Jump to navigation
Jump to search
scientific article published on 01 January 2000
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML) |
scientific article published on 01 January 2000 |
Statements
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML) (English)
A Ganser
G Heil
G Seipelt
W Hofmann
J T Fischer
W Langer
W Brockhaus
K Kolbe
T H Ittel
N Brack
H G Fuhr
P Knuth
K Höffken
L Bergmann
1 January 2000